Reference group choice and antibiotic resistance outcomes

Emerging Infectious Diseases

Volumn 10, Issue 6, 2004, Pages 1125-1128

  Kaye, Keith S ^a,d   Engemann, John J ^a   Mozaffari, Essy ^b   Carmeli, Yehuda ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Box 3152 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTEROCOCCUS; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OUTCOMES RESEARCH; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 2542631323     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1006.020665     Document Type: Article

References (14)

1. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36:1433-7.
2. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA. 1999;282:1745-51.
3. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis. 1996;23:1234-9.
4. Menon KV, Whiteley MS, Burden P, Galland RB. Surgical patients with methicillin resistant Staphylococcus aureus infection: an analysis of outcome using P-POSSUM. J R Coll Surg Edinb. 1999;44:161-3.
5. Montecalvo MA, Jarvis WR, Uman J, Shay DK, Petrullo C, Horowitz HW, et al. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol. 2001;22:437-42.
6. Newell KA, Millis JM, Arnow PM, Bruce DS, Woodle ES, Cronin DC, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation. 1998;65:439-42.
7. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999;20:408-11.
8. Auburtin M, Porcher R, Bruneel F, Scanvic A, Trouillet JL, Bedos JP, et al. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med. 2002;165:713-7.
9. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223-8.
10. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592-8.
11. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med. 1998;158:182-9.
12. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med. 1998;158:522-7.
13. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med. 2001;135:484-92.
14. Howard D, Cordell R, McGowan JE Jr, Packard RM, Scott RD, Solomon SL, et al. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop. Clin Infect Dis. 2001;33:1573-8.